Related Experiment Videos
[The effect of dipyridamole on coagulation status in stenocardia]
Bilten Za Hematologiju I Transfuziju
|January 1, 1978
Insights
Dipyridamole effectively inhibits platelet aggregation and adhesion in patients with coronary insufficiency. This study confirms its antiplatelet effects over a one-year treatment period.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Context:
- Coronary insufficiency poses significant cardiovascular risks.
- Platelet aggregation is a key factor in thrombotic events.
- Dipyridamole is a medication used to prevent blood clots.
Purpose:
- To evaluate the antiplategation effect of Dipyridamole in patients with coronary insufficiency.
- To assess changes in platelet aggregation and adhesion during a one-year treatment course.
Summary:
- Thirty patients with coronary insufficiency received Dipyridamole (300 mg/day) for one year.
- Platelet aggregation and adhesion were monitored before and during treatment.
- In vitro laboratory tests confirmed Dipyridamole's ability to inhibit platelet aggregation.
Impact:
- Provides evidence for Dipyridamole's efficacy in managing platelet-related complications in coronary insufficiency.
- Supports the use of Dipyridamole as an antiplatelet agent in clinical practice.
- Contributes to understanding the long-term effects of Dipyridamole on platelet function.
Abstract:
The laboratory examination of Dipyridamole concerning its antiaggregation effect is presented in the paper. Thirty patients with coronary insufficiency have been taking Dipyridamole for one year. The average dosage was four pills à 75 mg of Dipyridamole a day. The aggregation and adhesion of the platelets with the examined patients was checked before and during the treatment. The inhibition platelet aggregation with Dipyridamole has been confirmed in vitro.